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This editorial refers to ‘International differences in clini-
cal characteristics, management, and outcomes in acute
heart failure patients: better short-term outcomes in
patients enrolled in Eastern Europe and Russia in the PRO-
TECT trial,’ by R.J. Mentz et al., published in this issue on
pages 614–624.
Randomized trials that affect regulatory approval, guideline, and
third party payer considerations in patients with cardiovascular dis-
ease have increasingly required a relatively large number of patients
and reliance upon geographic locations around the world. The rea-
sons for inclusion of geographic locations around the world in these
large-scale studies varies but, in general, these are related to speed
of recruitment and costs. Centres in several parts of the world
such as Eastern Europe have a relatively lower cost per site and
a record of relatively rapid recruitment. The wide geographic and
ethnic spectrum of patients in these large-scale trials has impor-
tant advantages beyond ease of recruitment and costs, including
worldwide applicability of results and impact upon global health.
There are, however, disadvantages, including increased patient het-
erogeneity and the number of sites, often with a low number of
patients per site.1–3 These disadvantages are of particular con-
cern in designing and interpreting trials in patients with heart failure
(HF). Trials of new strategies in patients with myocardial infarction,
atrial fibrillation, and hypertension, for example, have commonly
accepted definitions for inclusion and for endpoint adjudication
while the definition of HF hospitalization, an inclusion criteria and
a component of the primary endpoint in many large HF trials, is
more problematic. It is often difficult on clinical grounds to be
sure that patients with chronic HF have worsening heart failure
that requires hospitalization. Various definitions, such as the need
for intravenous therapy and an overnight stay have been used to
define ‘hospitalization for HF’. Changing health-care practices in
many areas provide a challenge to this definition in that, increas-
ingly, patients with worsening signs or symptoms of HF may receive
intravenous diuretics in an infusion unit or outpatient setting with-
out an overnight stay in a hospital. There have been several studies
of geographic variation in large-scale HF trials that have pointed
out some of the difficulties in assuming that the overall results of a
trial apply equally to all of the geographic areas included.1,4–6
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.. Mentz et al.7 have analysed data from the PROTECT trial in which
2033 patients with acute HF and renal dysfunction hospitalized at
173 sites in 17 countries were randomized to rolofylline or placebo
in an attempt to explore the implications of geographic distribution.
They noted significant geographic differences in baseline character-
istics, HF phenotype, in-hospital diuretic and vasodilator strategies,
and length of stay. Following multivariable adjustment, region was
an independent predictor of the risk of mortality/hospitalization
at 60 days, with a then lowest risk in Russia vs. Western Europe
(HR 0.39) because of lower re-hospitalization, but little differ-
ence in long-term mortality. They comment on the clinical impli-
cations of these findings and emphasize that after risk adjustment
re-hospitalization rather than mortality was the driving factor for
geographic differences in composite outcomes and note that these
findings are consistent with previous studies showing a poor cor-
relation between re-hospitalization and mortality.1,4–6
While the geographic variations noted by Mentz et al.7 and
others1,4–6 in patients with HF clearly influence the rate of
re-hospitalizations, they may also influence mortality. For example,
in the Everest trial that enrolled 4,133 patients hospitalized with
worsening chronic HF and a reduced ejection fraction the mortality
was 30% in North America compared with 20% in Eastern Europe.1
In the recent TOPCAT trial8 evaluating the role of spironolac-
tone in 3,445 patients with HF with preserved ejection fraction
(HFpEF) the placebo cardiovascular mortality rates in patients from
Russia and the Republic of Georgia were several-fold less than in
those patients recruited from the Americas (Canada, USA, Brazil,
and Argentina). Patients could be included into TOPCAT either
on the basis of a previous hospitalization, a major component of
which was HF or signs and or symptoms of HF with an elevated
BNP or N-terminal pro-BNP. The vast majority of patients ran-
domized from Russia and the Republic of Georgia were included
on the basis of a previous history of hospitalization for HF. The
non-specific definition of HF, as alluded to above, may have resulted
in many patients with shortness of breath or dyspnoea owing to
obesity, chronic obstructive pulmonary disease (COPD), or other
factors being classified as having a hospitalization for HF. While
the explanation for the significant difference in mortality between
patients randomized from Russia and the Republic of Georgia
compared with the Americas remains uncertain, this difference
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makes interpretation of the overall results, which failed to show
a significant benefit of spironolactone on the primary endpoint
(which included the combination of cardiovascular mortality, resus-
citated cardiac arrest, and re-hospitalization for HF) difficult to
interpret. This was because in approximately half of the patients
recruited from the Americas, who had a placebo event rate com-
parable to previous studies of patients with HFpEF, there was a
significant reduction in the primary endpoint, whereas in Russia and
the Republic of Georgia, where the placebo event rate was com-
parable to patients with a risk factor such as hypertension without
evidence of HF, it would be difficult to detect a beneficial effect on
the primary endpoint given the overall sample size and the number
of patients recruited from these countries.
The issues raised by Mentz et al.7 and TOPCAT8 pose a prob-
lem for regulators, guideline committees, third party payers, and
individual clinicians in deciding whether or not the results of
a large-scale multinational trial applies to the patients they are
responsible for. Ideally, one would design and carry out these
large-scale pivotal trials in geographic areas with similar practice
patterns and baseline cardiovascular risk and/or have a sufficient
number of patients from a geographic region to reach a meaningful
conclusion as to the effectiveness and safety of a given strategy
in that region. However, in view of the need for large numbers of
patients it is, likely that we will continue to face the dilemma posed
by geographic variation. The differences noted by Mentz et al.7 are
however just the tip of the iceberg in that there are many other
factors that have not been adequately addressed in these analyses,
including genetic background, dietary preferences, lifestyle, social
support, mental status, and wellbeing, that may influence the effect
of a strategy on clinical outcomes. For example, an ethnic group
or individuals from a particular geographic area may consume a
diet higher in sodium than in another area, such that an agent that
reduces salt intake or increases sodium excretion could be effective
in the first group of patients while potentially harmful in the other
group with a lower sodium intake. There may be no easy solution
to the applicability of the results of large-scale multinational trials to
patients in the USA, Central Europe, or any other geographic area
when geographic differences are detected. We should, however,
make a greater effort to understand the potential baseline differ-
ences and practice patterns in individual geographic regions before
undertaking a large-scale international trial. A pre-trial registry
simulating the execution of the trial but without intervention may
identify characteristics of the patient population that can be site-
or region-specific.9 Only after examining pre-trial registry data
should sites be selected. This will allow us to understand not only
the potential of a site to enrol patients but will also ensure some
homogeneity of the patient population. There should also be clear
and objective definitions of the inclusion criteria and if a history of
HF is one of the criteria for inclusion, as it often is, there should be
objective means of verifying that the patients symptoms are caused
by HF, for example by requiring evidence of an elevated BNP or
NT pro-BNP level. While not a perfect guide to the presence of
worsening HF in a patient with chronic HF, biomarkers such as
BNP provide at least an easily verifiable and objective means that


















































































.. in Everest the medium BNP was 1031 pg/mL in North America
compared with 536 pg/mL in Eastern Europe.1 When unexpected
geographic differences appear, as they frequently do, these should
prompt a thorough analysis of potential factors that could account
for the differences. The sample size of the trial may not allow sta-
tistical validity comparing the results of one region with another.
However, when differences are detected and the majority of
patients and or events are obtained from regions where there has
been particularly rapid recruitment, and/or have a different pattern
of health-care delivery, one should be reassured that the placebo
event rates between regions are similar. Adjustment of baseline
factors and propensity matching may help in reassuring us as to the
applicability of the results across geographic regions but owing to
the many potential differences in ethnicity, life style, and health-care
delivery between regions it would be prudent to maintain a high
degree of scepticism before adopting or rejecting any new strategy
if large geographic differences are detected but not explained.
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